So far, enoblituzumab has been evaluated in combination with retifanlimab in a Phase 2 clinical study of a chemotherapy-free regimen for front-line patients with squamous cell carcinoma of the head and neck (SCCHN) and who are PD-L1-positive; it has also been used with tebotelimab in SCCHN patients who are PD-L1 negative [43,45,46]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.